Therapeutic Antibodies DigiTAb
PLA submitted Aug. 6 for treatment of the effects of digoxin toxicity. If approved, DigiTAB will be a direct competitor to Glaxo Wellcome's Digibind and will be marketed in the U.S. by Altana
PLA submitted Aug. 6 for treatment of the effects of digoxin toxicity. If approved, DigiTAB will be a direct competitor to Glaxo Wellcome's Digibind and will be marketed in the U.S. by Altana